Topical compositions and methods of using the same
The present invention generally relates to topical compositions and methods of using the same. The topical compositions may comprise a hydrophilic composition and a hydrophobic composition in admixture. The hydrophobic composition may include a nitric oxide-releasing compound such as, for example, a diazeniumdiolate functionalized co-condensed silica particle. In some embodiments, the topical composition may be self-emulsifying. Further described herein are kits comprising a hydrophilic composition and a hydrophobic composition.
1. A topical composition comprising:
a first composition and a second composition in admixture,
wherein the first composition is a hydrogel having a pH of about 4 to about 5 and the hydrogel has a buffer capacity to maintain the pH of the admixture within about 2 pH units of the hydrogel; wherein the first composition comprises a polymer, polyhydric alcohol, and water;
wherein the second composition comprises a hydrophobic base, an amphiphilic compound, and an active pharmaceutical ingredient comprising a diazeniumdiolate functionalized macromolecule; and
wherein the diazeniumdiolate functionalized macromolecule is present in the second composition at a concentration from about 0.01% to about 30% by weight of the second composition.
2. The composition of claim 1 , wherein the hydrogel has a buffer capacity to maintain the pH of the admixture within about 1 pH unit of the hydrogel.
3. The composition of claim 1 , wherein the hydrogel has a buffer capacity to maintain the pH of the admixture within about 0.5 pH units of the hydrogel.
4. The composition of claim 1 , wherein the second composition comprises at least two hydrophobic bases.
5. The composition of claim 1 , wherein the diazeniumdiolate functionalized macromolecule is present in the second composition at a concentration from about 0.01% to about 20% by weight of the second composition.
6. The composition of claim 1 , wherein the diazeniumdiolate functionalized macromolecule comprises a NO-releasing co-condensed silica particle.
7. The composition of claim 1 , wherein the diazeniumdiolate functionalized macromolecule comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyl trimethoxysilane (MAP3) and tetra methyl orthosilicate (TMOS) and/or diazeniumdiolated methylaminopropyl trimethoxysilane (MAP3) and tetraethyl orthosilicate (TEOS).
8. The composition of claim 1 , wherein the diazeniumdiolate functionalized macromolecule is present in the second composition at a concentration of about 4% by weight of the second composition.
9. The composition of claim 1 , wherein the diazeniumdiolate functionalized macromolecule is present in the second composition at a concentration of about 8% by weight of the second composition.
10. The composition of claim 1 , wherein the diazeniumdiolate functionalized macromolecule is present in the second composition at a concentration of about 12% by weight of the second composition.
11. The composition of claim 1 , wherein the first composition comprises a phosphate buffer.
12. The composition of claim 1 , wherein the first composition comprises acetic acid and an acetate.
13. A topical composition comprising:
a first composition and a second composition in admixture,
wherein the first composition is a hydrogel that has a buffer capacity to maintain the pH of the admixture within about 2 pH units of the hydrogel; wherein the first composition comprises a polymer, polyhydric alcohol, and water;
wherein the second composition comprises at least two hydrophobic bases, at least one amphiphilic compound, and an active pharmaceutical ingredient comprising a diazeniumdiolate functionalized macromolecule; and
wherein the diazeniumdiolate functionalized macromolecule is present in the second composition at a concentration from about 0.01% to about 30% by weight of the second composition.
14. The composition of claim 13 , wherein the first composition is a hydrogel having a pH of about 4 to about 6.
15. The composition of claim 13 , wherein the hydrogel has a buffer capacity to maintain the pH of the admixture within about 1 pH unit of the hydrogel.
16. The composition of claim 13 , wherein the hydrogel has a buffer capacity to maintain the pH of the admixture within about 0.5 pH units of the hydrogel.
17. The composition of claim 13 , wherein the diazeniumdiolate functionalized macromolecule comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyl trimethoxysilane (MAP3) and tetra methyl orthosilicate (TMOS) and/or diazeniumdiolated methylaminopropyl trimethoxysilane (MAP3) and tetraethyl orthosilicate (TEOS).
18. A method of treating skin of a subject, the method comprising:
administering an admixture to the skin of the subject, wherein the admixture comprises a first composition and a second composition,
wherein the first composition is a hydrogel having a buffer capacity to maintain the pH of the admixture within about 2 pH units of the hydrogel; wherein the first composition comprises a polymer, polyhydric alcohol, and water;
wherein the second composition comprises at least one hydrophobic base, at least one amphiphilic compound, and an active pharmaceutical ingredient, the active pharmaceutical ingredient comprising a diazeniumdiolate functionalized macromolecule; and
wherein the diazeniumdiolate functionalized macromolecule is present in the second composition at a concentration from about 0.01% to about 30% by weight of the second composition, thereby treating the skin of the subject.
19. The method of claim 18 , wherein the subject has atopic dermatitis.